Altered expression of noncanonical Wnt pathway genes in paediatric and adult adrenocortical tumours

The role of planar cell polarity (Wnt/PCP) and calcium‐dependent (Wnt/Ca) noncanonical Wnt pathways in adrenocortical tumours (ACTs) is unknown.

[1]  E. Lalli,et al.  Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  F. Saggioro,et al.  Components of the Canonical and Non-Canonical Wnt Pathways Are Not Mis-Expressed in Pituitary Tumors , 2013, PloS one.

[3]  R. Kuick,et al.  Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin. , 2012, The American journal of pathology.

[4]  Hans Clevers,et al.  Wnt/β-Catenin and MAPK Signaling: Allies and Enemies in Different Battlefields , 2012, Science Signaling.

[5]  G. Hammer,et al.  Adrenocortical stem and progenitor cells: Implications for adrenocortical carcinoma , 2012, Molecular and Cellular Endocrinology.

[6]  A. Latronico,et al.  Insulin-like growth factor system on adrenocortical tumorigenesis , 2012, Molecular and Cellular Endocrinology.

[7]  J. Bertherat,et al.  Wnt/β-catenin signalling in adrenal physiology and tumour development , 2012, Molecular and Cellular Endocrinology.

[8]  M. Fassnacht,et al.  TP53 germline mutations in adult patients with adrenocortical carcinoma. , 2012, The Journal of clinical endocrinology and metabolism.

[9]  A. Kikuchi,et al.  Wnt5a: its signalling, functions and implication in diseases , 2012, Acta physiologica.

[10]  L. Ramalho,et al.  Wnt/beta-catenin pathway deregulation in childhood adrenocortical tumors. , 2011, The Journal of clinical endocrinology and metabolism.

[11]  T. L. Mazzuco,et al.  Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations. , 2011, The Journal of clinical endocrinology and metabolism.

[12]  Martin Fassnacht,et al.  Adrenocortical carcinoma: a clinician's update , 2011, Nature Reviews Endocrinology.

[13]  T. Giordano.  Classification of adrenal cortical tumors: promise of the 'molecular' approach. , 2010, Best practice & research. Clinical endocrinology & metabolism.

[14]  J. Bertherat,et al.  β-Catenin Activation Is Associated with Specific Clinical and Pathologic Characteristics and a Poor Outcome in Adrenocortical Carcinoma , 2010, Clinical Cancer Research.

[15]  J. Bertherat,et al.  Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. , 2010, Cancer research.

[16]  Yingqun Wang,et al.  Wnt/Planar cell polarity signaling: A new paradigm for cancer therapy , 2009, Molecular Cancer Therapeutics.

[17]  J. Scheys,et al.  In search of adrenocortical stem and progenitor cells. , 2009, Endocrine reviews.

[18]  J. Jessen.  Noncanonical Wnt signaling in tumor progression and metastasis. , 2009, Zebrafish.

[19]  F. Beuschlein,et al.  Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma , 2009, Cancer.

[20]  Hideki Yamamoto,et al.  Tumor formation due to abnormalities in the β‐catenin‐independent pathway of Wnt signaling , 2008, Cancer Science.

[21]  I. Bourdeau,et al.  Frequent mutations of β‐catenin gene in sporadic secreting adrenocortical adenomas * , 2007, Clinical endocrinology.

[22]  G. Turashvili,et al.  Wnt Signaling Pathway in Mammary Gland Development and Carcinogenesis , 2007, Pathobiology.

[23]  I. Ng,et al.  Prickle-1 negatively regulates Wnt/beta-catenin pathway by promoting Dishevelled ubiquitination/degradation in liver cancer. , 2006, Gastroenterology.

[24]  R. Nusse,et al.  Purified Wnt5a Protein Activates or Inhibits β-Catenin–TCF Signaling Depending on Receptor Context , 2006, PLoS biology.

[25]  Jeffery R Barrow,et al.  Wnt/PCP signaling: a veritable polar star in establishing patterns of polarity in embryonic tissues. , 2006, Seminars in cell & developmental biology.

[26]  M. Katoh,et al.  WNT/PCP signaling pathway and human cancer (review). , 2005, Oncology reports.

[27]  T. Andersson,et al.  Wnt-5a protein expression in primary dukes B colon cancers identifies a subgroup of patients with good prognosis. , 2005, Cancer research.

[28]  M. de Castro,et al.  Inheritance of R337H p53 gene mutation in children with sporadic adrenocortical tumor. , 2005, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[29]  G. Brabant,et al.  Wnt-5a has tumor suppressor activity in thyroid carcinoma , 2005, Oncogene.

[30]  E. Pinto,et al.  Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors. , 2004, Arquivos brasileiros de endocrinologia e metabologia.

[31]  M. Bittner,et al.  Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. , 2002, Cancer cell.

[32]  E. Pinto,et al.  An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. , 2001, The Journal of clinical endocrinology and metabolism.

[33]  B. Figueiredo,et al.  [Childhood adrenocortical tumors]. , 1997, Arquivos brasileiros de endocrinologia e metabologia.

[34]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[35]  D. Schteingart.  Transcriptome Analysis Reveals that p53 and β-Catenin Alterations Occur in a Group of Aggressive Adrenocortical Cancers , 2011 .

[36]  W. Mcdougal.  An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. , 2002, The Journal of urology.